Table 2.
Effects of STN DBS during the off-medication condition
| Mean±SD scores* (possible range) |
Baseline (n=41) |
Baseline of 8-year follow-up (n=12) |
1 year post-op | 5 years post-op | 8 years post-op | p Value (1 year vs baseline) | p Value (5 years vs baseline) | p Value (8 years vs baseline) |
|---|---|---|---|---|---|---|---|---|
| Total UPDRS-III (0–108) |
50.3±15.8 | 57±15.2 | 22.9±12.8 | 33.7±8.7 | 36.2±16.9 | <0.001 | <0.001 | <0.001 |
| Tremor (0–28) | 7.3±4.1 | 7.9±3.6 | 2±2.6 | 1.9±1.6 | 1.8±1.8 | <0.001 | <0.001 | <0.001 |
| Rigidity (0–20) | 11.5±4.4 | 13±4.1 | 5.3±3.6 | 6.3±2.9 | 6.5±5 | <0.001 | <0.001 | <0.001 |
| Bradykinesia (0–36) | 21.8±7.1 | 25±6.5 | 11.8±7.1 | 18.3±5 | 19.2±8.4 | <0.001 | 0.03 | 0.019 |
| Axial (0–24) | 9.7±4.6 | 11.1±5.4 | 4.5±3.5 | 7.7±3.1 | 8.7±4.7 | <0.001 | 0.027 | 0.03 |
| UPDRS-II (ADL) (0–52) | 23.3±7.4 | 29.4±6.8 | 15.6±8.4 | 20.7±7 | 21±7.5 | <0.001 | 0.194 | 0.043 |
| On–off fluctuation (0–7) | 4.7±1.4 | 5.6±1.2 | 2.3±1.8 | 2.5±1.8 | 2.8±1.8 | <0.001 | <0.001 | 0.006 |
| Speech intelligibility (0–100) | 91.9±11.8 | 80.8±18.7 | 70.2±7.2 | 51.7±4.6 | 63.5±2.1 | >0.05 | <0.001 | <0.001 |
*For all outcome measures, higher scores indicate worse condition but for speech intelligibility, where higher scores are indicative of better performance.
ADL, activities of daily living; DBS, deep brain stimulation; STN, subthalamic nucleus; UPDRS, Unified Parkinson's Disease Rating Scale.